other material
confidence high
sentiment positive
materiality 0.75
Nurix reports positive Phase 1 data for BTK degrader NX-2127; 33% ORR in heavily pretreated CLL
Nurix Therapeutics, Inc.
- ORR of 33% (95% CI 12-62%) in 23 CLL patients who failed median 5 prior therapies, 78% prior BTK+BCL2 inhibitors.
- 48% of CLL patients had BTK resistance mutations; NX-2127 showed activity regardless of mutational status.
- Median follow-up 5.6 months; 14 of 23 CLL patients remained on treatment as of Sept 21, 2022 data cut.
- BTK mutations resistant to covalent and non-covalent inhibitors remained susceptible to degradation by NX-2127.
- Safety profile consistent with prior Phase 1a results and BTK-targeted therapies in heavily pretreated patients.